Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16

Journal of Natural Products

Volumn 60, Issue 8, 1997, Pages 752-754

  Pettit, George R ^a   Xu, Jun Ping ^a   Hogan, Fiona ^a   Williams, Michael D ^a   Doubek, Dennis L ^a   Schmidt, Jean M ^a   Cerny, Ronald L ^b   Boyd, Michael R ^c  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; DEPSIPEPTIDE; DOLASTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG ISOLATION; DRUG STRUCTURE; INFRARED SPECTROMETRY; LEUKEMIA CELL LINE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PAPUA NEW GUINEA; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; APLYSIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPSIPEPTIDES; HUMANS; LEUKEMIA P388; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; SPECTROPHOTOMETRY, INFRARED; TUMOR CELLS, CULTURED;

ANASPIDEA; AURICULARIA; DOLABELLA AURICULARIA; LEPUS;

EID: 0030796445     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np9700230     Document Type: Article

References (19)

1. Antineoplastic Agents. 368. Part 367: Maki, A.; Raza, S.; Govindaraju, K. D.; Pettit, G. R.; Al-Katib, A. Anti-Cancer Drugs, submitted.
2. (2) For leading references see: (a) Pettit, G. R.; Srirangam, J. K.; Singh, S. B.; Williams, M. D.; Herald, D. L.; Barkóczy, J.; Kantoci, D.; Hogan, F. J. Chem. Soc., Perkin Trans. 1 1996, 859-863. (b) Pettit, G. R.; Srirangam, J. K.; Barkóczy, J.; Williams, M. D.; Durkin, K. P. M.; Boyd, M. R.; Bai, R.; Hamel, E.; Schmidt, J. M.; Chapuis, J.-C. Anti-Cancer Drug Des. 1995, 10, 529-544. (c) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems. R. J. J. Am. Chem. Soc. 1987, 109, 6883-6885.
3. For leading references see: (a) Pettit, G. R.; Srirangam, J. K.; Singh, S. B.; Williams, M. D.; Herald, D. L.; Barkóczy, J.; Kantoci, D.; Hogan, F. J. Chem. Soc., Perkin Trans. 1 1996, 859-863. (b) Pettit, G. R.; Srirangam, J. K.; Barkóczy, J.; Williams, M. D.; Durkin, K. P. M.; Boyd, M. R.; Bai, R.; Hamel, E.; Schmidt, J. M.; Chapuis, J.-C. Anti-Cancer Drug Des. 1995, 10, 529-544. (c) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems. R. J. J. Am. Chem. Soc. 1987, 109, 6883-6885.
4. For leading references see: (a) Pettit, G. R.; Srirangam, J. K.; Singh, S. B.; Williams, M. D.; Herald, D. L.; Barkóczy, J.; Kantoci, D.; Hogan, F. J. Chem. Soc., Perkin Trans. 1 1996, 859-863. (b) Pettit, G. R.; Srirangam, J. K.; Barkóczy, J.; Williams, M. D.; Durkin, K. P. M.; Boyd, M. R.; Bai, R.; Hamel, E.; Schmidt, J. M.; Chapuis, J.-C. Anti-Cancer Drug Des. 1995, 10, 529-544. (c) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems. R. J. J. Am. Chem. Soc. 1987, 109, 6883-6885.
5. (a) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Fujii, Y.; Kizu, H.; Boyd, M. R.; Boettner, F. E.; Doubek, D. L.; Schmidt, J. M.; Chapuis, J.-C.; Michel, C. Tetrahedron 1993, 49, 9151-9170.
6. (b) Pettit, G. R.; Herald, D. L.; Singh, S. B.; Thornton, T. J.; Mullaney, J. T. J. Am. Chem. Soc. 1991, 223, 6692-6693.
7. (a) Sone, H.; Shibata, T.; Fujita, T.; Ojika, M.; Yamada, K. J. Am. Chem. Soc. 1996, 118, 1874-1880.
8. (b) Qjika, M.; Nagoya, T.; Yamada, K. Tetrahedron Lett. 1995, 36, 7491-7494.
9. (c) Ishiwata, H.; Sone, H.; Kigoshi, H.; Yamada, K. Tetrahedron 1994, 50, 12853-12882.
10. (d) Ojika, M.; Nemoto, T.; Yamada, K. Tetrahedron Lett. 1993, 34, 3461-3462.
11. (5) Schaufelberger, D. E.; Pettit, G. R. J. Liquid Chromatogr. 1989, 12, 1909-1917. Pettit, G. R.; Kamano, Y.; Schaufelberger, D. E.; Herald, C. L.; Blumberg, P. M.; May, S. W. J. Liquid Chromatogr. 1989, 12, 553-561.
12. Schaufelberger, D. E.; Pettit, G. R. J. Liquid Chromatogr. 1989, 12, 1909-1917. Pettit, G. R.; Kamano, Y.; Schaufelberger, D. E.; Herald, C. L.; Blumberg, P. M.; May, S. W. J. Liquid Chromatogr. 1989, 12, 553-561.
13. Zabriskie, T. M.; Foster, M. P.; Stout, T. J.; Clardy, J.; Ireland, C. M. J. Am. Chem. Soc. 1990, 112, 8080-8084.
14. McDonald, L. A.; Foster, M. P.; Phillips, D. R.; Ireland, C. M. J. Org. Chem. 1992, 57, 4616-4624.
15. 3CN (9:1) for 2-hydroxyisovaleric acid; detection at λ 230.4 and 550 nm. By comparison of the retention times (min) with those of the authentic L- and D-a-amino and hydroxy acids [L-MeVal (6.79), D-MeVal (10.91), L-Pro (8.61), D-Pro (18.80), L-Lac (14.14), (S)-Hiv (12.04), and (R)-Hiv (19.52)], the retention times (min) and absolute configuration of the six components in the acid hydrolysate of dolastatin 16 (3) were found to be 8.75 (L-Pro x 3), 10.53 (D-MeVal), 14.50 (L-Lac), and 19.02 CR-Hiv).
16. Boyd, M. R. The Future of New Drug Development. Section I. Introduction to Cancer Therapy. In Current Therapy in Oncology; Niederhuber, J. E., Ed.; B. C. Decker: Philadelphia, 1993; pp 11-22.
17. Boyd, M. R.; Paull, K. D. Drug Development Research 1995, 34, 91-109.
18. Monks, A.; Scudiero, P.; Skehan, P.; Shoemaker, R.; Paull, K; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Boyd, M. R. J. Natl. Cancer Inst. 1991, 83, 757-766.
19. Pettit, G. R.; Thornton, T. J.; Mullaney, J. T.; Boyd, M. R.; Herald, D. L.; Singh, S. B; Flahive, E. J. Tetrahedron 1994, 50, 12097-12108.